Isotretinoin

The severe-acne drug — an oral retinoid that shrinks sebaceous glands. It circulates in enhancement spaces because steroid use causes acne, creating a self-medication loop the drug was never meant to sit in.

Isotretinoin is a retinoid — a vitamin A derivative — and it is the only acne treatment that acts on all four drivers of the disease at once. It shrinks sebaceous glands dramatically and durably, which cuts oil production, and that in turn removes the environment the acne-associated bacteria need, reduces follicular plugging and lowers inflammation. The gland shrinkage is why it can produce lasting remission rather than suppression, and it also explains the drying of lips, eyes and mucous membranes. It would be wrong to file every side effect under that theme though: this is a systemic retinoid with multi-organ toxicity, and its serious harms have nothing to do with dryness.

Dermatology-grade evidence: highly effective for severe recalcitrant nodular acne; relapse and retreatment occur.

• The most effective treatment available for severe, nodular and treatment-resistant acne, with decades of randomised evidence and durable remission in a majority of patients after a single course.
• The teratogenicity is not disputed and is severe: exposure in pregnancy causes a characteristic pattern of major birth defects, which is why prescription is governed by mandatory pregnancy-prevention programmes in most countries.
• The psychiatric question is the genuinely contested one. Regulators require depression and suicidality warnings; large cohort studies have produced mixed results and some find acne itself, untreated, carries elevated psychiatric risk. The honest position is that a signal exists, causality is unresolved, and the warning is taken seriously.
• Inflammatory bowel disease was a long-standing concern; larger studies and meta-analyses have generally not supported a causal link, though the topic remains discussed.
• Raised triglycerides and liver enzymes are common, dose-related and reversible, which is why bloodwork is standard during treatment.

Food instructions are specific to the product dispensed and the formulations are not interchangeable — some may be taken with or without food, others must not. Follow the exact label and prescriber instruction for the product you were given rather than any general rule. Half-life around 10-20 hours for the parent drug. Standard practice is to avoid pregnancy for a defined period after the last dose, and to avoid blood donation over the same window because donated blood could reach a pregnant recipient.

Teratogenic to a degree few common drugs match — US prescribing runs through the iPLEDGE pregnancy-prevention program for that reason, and use outside it has no such guardrail. Very common mucocutaneous dryness, lipid and liver effects that need bloodwork monitoring (monitoring mitigates risk, it does not remove it), night-vision changes, and a long-argued psychiatric signal (depression reports; causality still debated). Combining it with a steroid cycle stacks two lipid/liver stressors while treating a symptom of the first one.

• Anyone pregnant, who could become pregnant without the mandatory prevention programme, or breastfeeding
• Anyone with significantly raised triglycerides or liver disease
• Anyone taking tetracycline antibiotics
• Anyone taking vitamin A supplements or desiccated liver products
• Anyone with a history of severe depression, without close psychiatric involvement

• Pregnancy — absolute. This is the single most important fact about the drug.
• Vitamin A supplements, cod liver oil and desiccated liver products, which stack additively toward retinoid toxicity.
• Tetracycline antibiotics, which together raise the risk of raised intracranial pressure.
• Alcohol, given the shared burden on liver and triglycerides.
• Waxing, laser and dermabrasion, which risk skin tearing during and for months after treatment.
• Anabolic steroids, which independently raise lipids and liver enzymes and are commonly used in the same demographic.

• Pregnancy testing before, during and after treatment, under the mandatory programme — this is the non-negotiable part.
• Liver enzymes and a fasting lipid panel, particularly triglycerides.
• Mood, explicitly and repeatedly, ideally with someone else watching too.
• Vision, especially night vision, and any severe headache with visual change, which needs urgent assessment.
• Skin and lips, which will dry and crack — expected rather than a warning sign.
• Musculoskeletal aches, common in people training hard, and bone effects are on the label.
• Severe abdominal pain, nausea or vomiting — pancreatitis is a labelled risk and can occur without extreme triglyceride levels.
• Any hearing change or ringing, which can persist after stopping.
• Any severe skin reaction — Stevens-Johnson syndrome and toxic epidermal necrolysis are reported, alongside hypersensitivity reactions.
• New or worsening bowel symptoms, since inflammatory bowel disease is covered in the labelling.

Skin and lip dryness resolve over weeks. Triglycerides and liver enzymes normalise. Sebaceous gland suppression persists for months, which is the entire point — the remission outlasts the drug. The pregnancy-prevention requirements continue for a defined period after the last dose and must be followed exactly, as must the blood-donation restriction. Anyone who experienced mood change during treatment should keep that under review afterwards rather than assuming it left with the drug.

US: prescription-only under the iPLEDGE program.

Papers about this compound, not proof of the claims above. A title says what was studied, which is sometimes a negative result or a different question entirely.

• Low-dose isotretinoin for the management of rosacea: A systematic review and meta-analysis
  J Eur Acad Dermatol Venereol, 2025
• Adverse Events in Isotretinoin Therapy: A Single-Arm Meta-Analysis
  Int J Environ Res Public Health, 2022
• Low-dose oral isotretinoin for the treatment of adult patients with mild-to-moderate acne vulgaris: Systematic review and meta-analysis
  Dermatol Ther, 2022

• Isotretinoin for acne vulgaris - an update on adverse effects and laboratory monitoringJ Dermatolog Treat · 2022
• Optimizing Isotretinoin Treatment of Acne: Update on Current Recommendations for Monitoring, Dosing, Safety, Adverse Effects, Compliance, and OutcomesAm J Clin Dermatol · 2020
• Isotretinoin and dermatosurgical proceduresIndian J Dermatol Venereol Leprol · 2019
• Isotretinoin-Induced ElkonyxisActas Dermosifiliogr · 2017
• Isotretinoin as a Multifunctional Anticancer Agent: Molecular Mechanisms, Pharmacological Insights and Therapeutic PotentialArch Pharm (Weinheim) · 2025
• Isotretinoin revisitedCutis · 1988
• Isotretinoin and night blindnessAustralas J Dermatol · 2014
• Low dose of isotretinoin: A comprehensive reviewDermatol Ther · 2020
• The safety of isotretinoin treatment in patients with bone fracturesPostepy Dermatol Alergol · 2019
• Isotretinoin-induced sacroiliitis in patients with hidradenitis suppurativa: a case-based reviewRheumatol Int · 2019
• The impact of isotretinoin on the pituitary-ovarian axis: An interpretative review of the literatureReprod Toxicol · 2021
• A review of isotretinoin in the treatment of frontal fibrosing alopeciaJ Cosmet Dermatol · 2024